Progress in the clinical application of immunosuppressive drugs in renal transplantation

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 6, 2001, Pages 763-770

  Wilkinson, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TACROLIMUS; UNCLASSIFIED DRUG;

ALLOGRAFT; ATHEROSCLEROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 0034762375     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200111000-00006     Document Type: Review

References (76)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Immunosuppressive medications for renal transplantation: A multiple-choice question
3. Incidence and long-term cost of steroid related side effects after renal transplantation
4. Maintenance immunosuppression: New agents and persistent dilemmas
5. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
6. Use of basiliximab and daclizumab in kidney transplantation
7. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis
8. Economic analysis of basiliximab in renal transplantation
9. Meta-analysis and economic analysis of basiliximab (Simulect) in renal transplantation. Transplant 11-16 May 2001; Chicago
10. North/South American, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral and corticosteroids. Transplant 2001; 11-16 May 2001; Chicago
11. One year results of a multicenter, open-label trial on safety and efficacy of Certican™ (RAD) used in combination with Simulect, corticosteroids, and full or reduced dose Neoral in renal transplantation. Transplant 2001; 11-16 May 2001; Chicago
12. Basiliximab induction is more effective than OKT3 in recipients of kidneys from donors older than 55 years in reducing acute rejection and improving graft survival. Transplant 2001; 11-16 May 2001; Chicago
13. Efficacy of daclizumab in an African-American and Hispanic transplant population
14. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation: 6-month analysis. Transprant 2001; 11-16 May 2001; Chicago
15. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
16. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric renal transplant recipients at risk of delayed graft function
17. The effect of daclizumab in a high-risk renal transplant population
18. A multi-center trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: An interim analysis
19. Inhibition of crossmatch (CMX) positivity between donor/recipient pairs using intravenous gammaglobulin (IVIG) with subsequent transplantation. Transplant 2001; 11-16 May 2001; Chicago
20. A randomized and prospective study comparing treatment with high dose intravenous gammaglobulin with monoclonal antibodies for the rescue of kidney grafts with steroid-resistant rejection. Transplant 2001; 11-16 May 2001; Chicago
21. Rapid corticosteroid withdrawal in simultaneous pancreas-kidney transprantation. Transplant 2001; 11-16 May 2001; Chicago
22. Two-year insulin independence and metabolic follow-up after islet-alone transplantation in autoimmune diabetes. Transplant 2001; 11-16 May 2001; Chicago
23. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol
24. Efficacy and safety of three months of tacrolimus/steroid/MMF followed by a controlled withdrawal of steroids or MMF: Results of a large, prospective, multicentre trial Transplant 2001; 11-16 May 2001; Chicago
25. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to know? Where do we go from here?
26. Pravastatin improves long-term graft and patient survival after kidney transprantation: An examination of five-year follow-up data. Transplant 2001; 11-16 May 2001; Chicago
27. Impact and management of hyperlipidemia post transplantation
28. Use of angiotensin-converting enzyme inhibitors and angiotensin II antagonists in renal transplantation: Delaying the progression of allograft nephropathy?
29. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy
30. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis
31. Withdrawal of steroids after renal transplantation - Clinical predictors of outcome
32. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts
33. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome
34. A meta-analysis of immunosuppression withdrawal trials in renal transplantation
35. Prednisone withdrawal in kidney transplant recipients on cycrosporine and mycophenolate mofetil - A prospective randomized study
36. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal alrograft rejection
37. Lack of long-term benefits of steroid withdrawal in renal transplant recipients
38. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival
39. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
40. Effect of mycophenolate mofetil on long-term outcomes in African -American renal transprant recipients
41. Cyclosporine A withdrawal in live related renal transplantation: A long-term study
42. Elective cyclosporine withdrawal 1 year after renal transplantation
43. A prospective, randomised study of withdrawal of cycrosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow-up data. Transplant 2001; 11-16 May 2001; Chicago
44. Nephrotoxicity of calcineurin inhibitors: New therapeutic approaches
45. Withdrawal of mycophenolate mofetil in stable renal transplant recipients
46. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: Meta-analysis of randomized trials
47. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
48. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenorate mofetil after cadaveric renal transplantation
49. Maintenance immunosuppression
50. Neoral and tacrolimus are associated with a decrease in chronic allograft failure as compared to Sandimmune. Transplant 2001; 11-16 May 2001; Chicago
51. Neoral® C-2 absorption profiling: A simple, accurate and precise predictor of rejection risk in renal transplantation. Transprant 2001; 11-16 May 2001; Chicago
52. Clinical benefit of Neoral dose monitoring with cycrosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients
53. Comparison of Neoral dose monitoring with cycrosporine trough levels versus 2-hr post-dose levels in stable liver transplant patients
54. Benefits of cycrosporine microemulsion (Neoral©) C-2 monitoring are sustained at one year in de novo liver transplant recipients. Transplant 2001; 11-16 May 2001; Chicago
55. Conversion of stable renal transplant recipients from cyclosporine microemulsion trough (C-0) to C-2 monitoring: Implications for exposure. Transplant 2001; 11-16 May 2001; Chicago
56. Use of C-2 monitoring to optimize cyclosporine microemulsion dosing in de novo renal transplant recipients: A safety analysis. Transplant 2001; 11-16 May 2001; Chicago
57. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
58. Sirolimus (rapamycin)-based therapy in human renal transprantation: Similar efficacy and different toxicity compared with cyclosporine: Sirolimus European Renal Transplant Study Group
59. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal alrografts
60. Efficacy of sirolimus compared with azathioprine for reduction of acute renal alrograft rejection: A randomized murticentre study
61. Sirolimus-tacrolimus combination immunosuppression
62. Two-year safety and efficacy of sirolimus in renal transplantation. Transplant 2001; 11-16 May 2001; Chicago
63. Comparison of sirolimus and mycophenolate mofetil on renal function and morphology in post-ischemic rat kidney. Transplant 2001; 11-16 May 2001; Chicago
64. Sirolimus (Rapamune) maintenance therapy permits early cyclosporine withdrawal resulting in improved renal function: 12-month results of the Tri-Continental Trial. Transplant 2001; 11-16 May 2001; Chicago
65. A prospective randomized trial of sirolimus vs. cyclosporine in kidney transplantation: Impact of calcineurin inhibitor elimination on renal function. Transplant 2001; 11-16 May 2001; Chicago
66. Improved kidney graft function in patients receiving sirolimus, cyclosporine and steroids: The role of cyclosporine blood concentration. Transplant 2001; 11-16 May 2001; Chicago
67. Improved renal function with cyclosporine elimination in sirolimus-treated renal transplant recipients: One-year results from a phase II trial. Transprant 2001; 11-16 May 2001; Chicago
68. Remarkably low rate of acute renal allograft rejection in African-Americans receiving sirolimus, low-dose tacrolimus, and corticosteroids: Preliminary results of a pilot study. Transplant 2001; 11-16 May 2001; Chicago
69. Comparison of mortality in all patients on dialysis, patients on dialysis transplantation, and recipients of first cadaveric transplant
70. Chronic cyclosporine nephropathy; the Achilles' heel of immunosuppressive therapy
71. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy
72. Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience
73. The use of mycophenolate mofetil in transplant recipients
74. Which patients benefit from cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy. Transplant 2001; 11-16 May 2001; Chicago
75. Conversion to sirolimus: How to determine the optimal window of opportunity. A single center experience. Transplant 2001; 11-16 May 2001; Chicago